Obinutuzumab

¥8,000.00

规格: 5mg

CAS号:949142-50-1

英文名字:afutuzumab

质量标准:>95%,蛋白原液
库存详情未设置 SKU: MB2774-1 分类: , ,

Obinutuzumab;afutuzumab
分子式:C6512H10060N1712O2020S44分子量:146.2KD
简介:Obinutuzumab (GA101) 是新型糖工程化II型CD20单克隆抗体,开发用来治疗非霍奇金淋巴瘤。
产品形式:蛋白原液。每种装于冻存管中,单抗质量为标示数量1MG或者5MG,体积根据其浓度不同略有不同。

质量标准:
Non-reduced CE-SDS:………………………………………….>90%;
SEC-HPLC:………………………………………………………….>95%;
Bacterial Endotoxins Test:…………………………………. .<10EU/ml
Residual Proteins of Host Cell: ……………………………. <100 ng/mg
Exogenous residual DNA: …………………………………. . <100pg/mg
Residual Protein A: ……………………………………………. .<100 ng/mg
Biological Activity:………………………………………….……. .80% to 125% of standard
储存条件:-70 ± 15℃for long-term storage, 2-8℃for short-term storage, away from light.
运输条件:干冰运输

使用建议:
meilunbio提供的产品为蛋白原液形式。每种装于冻存管中,单抗质量为标示数量1MG或者5MG,体积根据其浓度不同略有不同。
使用前可以根据自己实验需求进行稀释,溶剂建议用去离子无菌水(meilunbio货号MA0028,去离子无菌水(细胞培养用水))或者PBS(meilunbio货号MA0015PBS(1X),细胞培养级)。
不建议使用含有防腐成分的稀释液进行稀释,会增加细胞或者动物毒性。
稀释前,计算加入多少体积溶剂,请参考购买批次质检单上蛋白浓度,或者询问我司,
举例,质检单显示该批次单抗蛋白原液蛋白浓度为 50mg/ml
对应5MG包装的蛋白原液体积为5mg(质量)/50mg/ml(浓度)=0.1ML,
实验需求蛋白浓度为10mg/ml, 需要稀释倍数为 50/10=5, 则需要加入0.4ML,即400ul PBS或者无菌去离子水即可。
若给药量为固定质量值,比如单次给药0.5MG,对应蛋白原液给药体积为10ul,建议稀释后,提高给药体积降低误差,因为注射器或者移液器吸头残留会影响实验效果。
稀释后的蛋白溶液,可于2-8度冷藏避光保存不超过2周,不建议长期储存。
避免反复冻融,每次冻融蛋白活性会降低约5%左右。
生物活性(仅来自于公开文献,不保证其有效性)

描述
Obinutuzumab (GA101) a novel glycoengineered Type II CD20 monoclonal antibody in development for non-Hodgkin lymphoma.

靶点

CD20

体外

Obinutuzumab is found to be superior to rituximab and ofatumumab in the induction of direct cell death (independent of mechanical manipulation required for cell aggregate disruption formed by antibody treatment), whereas it is 10 to 1,000 times less potent in mediating CDC. Obinutuzumab shows superior activity to rituximab and ofatumumab in ADCC and whole-blood B-cell depletion assays, and is comparable with these two in ADCP. Obinutuzumab also shows slower internalization rate upon binding to CD20 than rituximab and ofatumumab.

体内

Obinutuzumab is more active than rituximab administered at similar doses on established RL tumors. The antitumor effect of obinutuzumab against RL xenografts is dose dependent in terms of tumor growth inhibition (TGI). TGI is calculated using NCI formula at day 34 and shows values of 25, 75, and 85% for the 10, 30, and 100 mg/kg dosages of obinutuzumab, respectively. The higher doses of 30 and 100 mg/kg of obinutuzumab significantly inhibit the growth of RL tumors and result in some complete tumor remissions (10% and 30%, respectively). Tolerability of obinutuzumab with these regimens is excellent and no significant modification of body weight is observed. Obinutuzumab induces a strong antitumor effect, including complete tumor remission in the SU-DHL4 model and overall superior efficacy compared with both rituximab and ofatumumab. Obinutuzumab plus bendamustine achieves superior tumor growth inhibition versus rituximab plus bendamustine and shows a statistically significant effect versus the respective single treatments. Obinutuzumab plus chemotherapy is superior to the respective monotherapies.

美仑相关产品推荐(更多相关靶点抑制剂请详询官网或客服)

产品编号

品名.

Target

MB2806

aflibercept

VEGFR

MB2786

Alemtuzumab

CD52

MB2787

Alirocumab

PCSK9

MB2789

Avelumab

PDL-1

MB2790

Atezolizumab

PDL-1

MB2791

Bevacizumab

VEGF

MB2792

Cetuximab

EGFR

MB2803

Daratumumab

CD38

MB2794

Denosumab

RANK Ligand

MB2023

Eculizumab

补体蛋白(C5)

MB2795

Etanercept

TNF

MB2797

Evolocumab

PCSK9

MB2773

Infliximab

TNF-α

MB2769

Ipilimumab

CTLA-4

MB2772

Matuzumab

EGFR

MB2766

Mepolizumab

IL-5

MB2767

Nivolumab

PD-1

MB2784

Adalimumab

TNF-α

MB2776

Ofatumumab

CD20

MB2777

Omalizumab

IgE

MB2781

Panitumumab

EGFR

MB2761

Pembrolizumab

PD-1

MB2762

Pertuzumab

HER2

MB2763

Ranibizumab

VEGFR

MB2938

Ramucirumab

VEGFR

MB2749

Rituximab

CD20

MB2757

Secukinumab

IL-17

MB2751

Tocilizumab/Atlizumab

IL-6 receptor

MB2753

Trastuzumab

ErbB2

MB2758

Ustekinumab

IL-12

用途及描述:仅供科研,严禁用于人体(For R&D Only)

我司所售出产品仅供于科研研究用途(非临床科研研究),每次销售产品行为都适用于我司网上所列明的通用销售条款

规格

5mg

相关文档

购物车